Bristol Myers Squibb stock holds steady as earnings and guidance frame the outlook

Bristol Myers Squibb (US0897961004) remains centered on its latest reported numbers: $46.4 billion in 2024 revenue, $12.1 billion in net income, and 2025 revenue guidance of about $45.8 billion. The company also reported adjusted EPS of $6.56 for 2024, giving investors a dated baseline for the shares.

Revenue still above $46 billion

The 2024 top line of $46.4 billion was supported by a year in which Bristol Myers Squibb kept a large commercial base in place while preparing for another year of patent pressure and portfolio shifts. The year also produced a net income figure of $12.1 billion, which gives the market a clean profit reference rather than a purely narrative update.

That combination matters because the company is not being judged on one quarter alone. A revenue base above $46 billion and net income above $12 billion in 2024 leaves the stock tied to execution, not just pipeline headlines.

Guidance near $45.8 billion

For 2025, Bristol Myers Squibb guided to revenue of about $45.8 billion, which is slightly below the 2024 level of $46.4 billion. The comparison gives a simple read-through: the company is planning around a lower sales base while trying to protect earnings quality.

Adjusted EPS of $6.56 in 2024 is the second key reference point, because it shows how much earnings power must be defended if sales flatten or soften in 2025. In investor terms, the gap between 2024 results and 2025 guidance is the main math to watch.

Pipeline and product mix

Bristol Myers Squibb still leans on a broad oncology and immunology franchise, with the product mix carrying more weight as older assets face pressure. That makes the company sensitive to how quickly newer therapies can offset the direction of the mature portfolio.

For the stock, the useful lens is not a broad company description but the relationship between current revenue scale, guided sales, and profit conversion. A business with $46.4 billion of revenue and $12.1 billion of net income has room, but the 2025 guide implies less slack than the 2024 base suggests.

Share-price reference point

As a market reference, the latest article uses the companys reported 2024 and 2025 figures as the current value anchor. Bristol Myers Squibb stock is therefore best read through its dated earnings base and guidance path, with $46.4 billion in 2024 revenue, $12.1 billion in 2024 net income, and about $45.8 billion in 2025 revenue guidance setting the frame.